Related Experiment Video
Updated: Jul 1, 2026
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
[Anticardiolipin and anti-beta2 glycoprotein-1 antibodies patients with breast carcinoma: a pilot study]
Irena Zimmermann-Górska1, Sylwia Grodecka-Gazdecka, Grazyna Białkowska-Puszczewicz
1Katedra i Klinika Reumatologiczno-Rehabilitacyjna i Chorób Wewnetrznych, Uniwersytet Medyczny im. Karola Marcinkowskiego, Poznań. zimmermanngorska@hotmail.com
Introduction:
Thrombosis - the main manifestation of antiphospholipid syndrome (APS) - is at the same time observed in some patients with malignancies.
Objectives:
Evaluation of prevalence of some antiphospholipid antibodies (aPL) in serum of patients with breast carcinoma and the possible correlation between aPL seropositivity and clinical symptoms.
Patients And Methods:
40 patients with breast carcinoma and 38 patients with non-malignant diseases of breast were studied. Anticardiolipin antibodies (aCL) and antibodies to beta2 glycoprotein-I (anti-beta2GPI) were detected by ELISA.
Results:
The aCL as well as anti-beta2GPI were positive in 1 patient with breast carcinoma, who at the same time presented with symptoms of APS. In the control group 2 patients were positive for anti-beta2GPI.
Conclusions:
We have not observed a difference of aPL prevalence between the group of patients with breast carcinoma and controls. The association of breast cancer and aPL seropositivity deserves further investigations.
